Cassava Sciences (SAVA)
(Delayed Data from NSDQ)
$28.39 USD
+4.69 (19.79%)
Updated Aug 15, 2024 04:00 PM ET
Pre-Market: $28.54 +0.15 (0.53%) 8:04 AM ET
4-Sell of 5 4
D Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
SAVA 28.39 +4.69(19.79%)
Will SAVA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SAVA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SAVA
Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates
Eli Lilly (LLY) Gets FDA Nod for Alzheimer's Drug Donanemab
SAVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Can Eli Lilly ETFs Surge on Approval of Alzheimer's Drug?
Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab (Revised)
Cassava Sciences, Inc. (SAVA)'s Technical Outlook is Bright After Key Golden Cross
Other News for SAVA
9 Health Care Stocks Whale Activity In Today's Session
Cautious Optimism Amidst Legal Challenges: Hold Rating on Cassava Sciences
Wall Street Breakfast: The Week Ahead
Cassava Sciences Q2 Earnings Review: So Many Questions, So Few Answers
Cassava Sciences, Inc. (SAVA) Q2 2024 Earnings Call Transcript